Chinese venture capital firms are doubling down on areas in which they have domain expertise as the spectrum of opportunities widens, industry participants told the AVCJ Forum.
The historical trend has been one of generalization, but there is now a growing appreciation that a concentrated focus can translate into better returns. “It’s proven to be a bad idea in the Chinese context...
China-based data storage software services provider XSKY has raised a RMB320 million ($45 million) Series D led by China's State Owned Capital Venture Capital Fund.
CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
KKR has agreed to buy a 54% stake in Indian drug maker J.B. Chemicals & Pharmaceuticals for INR31.1 billion ($416 million) and made an open offer for an additional 26% of the company.